Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights

negativeAutologous CAR TNegative

AI Analysis

Summary

Longitudinal analysis by Spherix Global Insights reveals that recent autoimmune CAR T trial pauses have increased safety concerns among rheumatologists, though autologous CAR T remains the leading approach. Systemic sclerosis is identified as the clearest near-term opportunity for immune reset therapy development.

Clinical Trial Data

Outcome Details

Safety concerns surge following recent trial pauses in autoimmune CAR T programs

Importance:5/10

Sentiment:

-0.60

CAR T therapyautoimmune diseasesafety concernstrial pausessystemic sclerosisrheumatologymarket sentiment

Related Companies

$GBCMD

Read the original article

Published by GlobeNewswire Clinical Studies on October 1, 2026 5:53 PM

Read Original